Danoprevir: First Global Approval.

Link to article at PubMed

Related Articles

Danoprevir: First Global Approval.

Drugs. 2018 Aug 16;:

Authors: Markham A, Keam SJ

Ascletis has developed danoprevir (Ganovo®), an orally-administered hepatitis C virus NS3 protease inhibitor, as a treatment for hepatitis C. Based on positive results in phase II and phase III trials in patients with hepatitis C, danoprevir, in combination with ritonavir, peginterferon alfa and ribavirin was recently approved for marketing in China for the treatment of treatment-naive patients with non-cirrhotic genotype 1b chronic hepatitis C. This article summarizes the milestones in the development of danoprevir leading to this first approval.

PMID: 30117020 [PubMed - as supplied by publisher]

Leave a Reply

Your email address will not be published.